RESUMEN
We have conducted an open, controlled study on the febrile neutropenia effects by Lenograstim (Granocyte) therapy following cytotoxic chemotherapy of cisplatinum and cyclophosphamide in patients with primary advanced epithelial ovarian cancer. Eligible patients (n = 17) were divided into 2 groups receiving a combined chemotherapy of intravenous cisplatinum (70 mg/m2) and cyclophosphamide (700 mg/m2) with or without the addition of Lenograstim. Subcutaneous administration of Lenograstim (100 micrograms/day) for 7 consecutive days was given from day 8 to day 14 of the 3rd to the 5th cycle of chemotherapy in Lenograstim treated patients. After 3 cycles of treatment, Lenograstim treated patients (group 1, n = 10) showed a significant improvement in white blood cell (WBC) count as compared with group 2 (control) of 7 patients (p = 0.00002). Group 1 patients also showed an increased C-reactive protein, though of no significance. There were no significant differences among the 2 groups regarding ESR, hematocrit, platelet counts and blood chemistry profiles. This preliminary data encourages more study of the benefits of Lenograstim in the treatment of ovarian cancer.
Asunto(s)
Administración Cutánea , Adolescente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Proteína C-Reactiva/análisis , Cisplatino/administración & dosificación , Ciclofosfamida/efectos adversos , Quimioterapia Combinada , Femenino , /administración & dosificación , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Humanos , Recuento de Leucocitos/efectos de los fármacos , Leucocitos/efectos de los fármacos , Recuento de Linfocitos , Persona de Mediana Edad , Neoplasias Glandulares y Epiteliales/tratamiento farmacológico , Neoplasias Ováricas/sangre , Proteínas Recombinantes/uso terapéuticoRESUMEN
Locally advanced cervical cancer could be treated with Interferon-alpha plus retinoic acid concomitant with standard radiotherapy. It showed some response in local control. The pattern of relapse and the survival of the patients should be observed in the follow-up period for the conclusion.
Asunto(s)
Adulto , Anciano , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Estudios de Casos y Controles , Quimioterapia Adyuvante/métodos , Femenino , Estudios de Seguimiento , Humanos , Interferón-alfa/administración & dosificación , Estudios Longitudinales , Persona de Mediana Edad , Resultado del Tratamiento , Tretinoina/administración & dosificación , Neoplasias del Cuello Uterino/tratamiento farmacológicoRESUMEN
Fifteen patients with recurrent, metastatic, or residual cervical cancer post radiotherapy were treated by combined cis-platinum 40 mg/m2 IV and mitomycin-C 30 mg/m2 IV in day 1, repeated every 4 weeks for 3-5 cycles. The maintained therapy was performed by mitomycin-C 2 mg/day orally for 7 days, every 4 weeks for 6 cycles. Six of 15 patients (40%) showed complete remission and are alive without disease after a follow-up period of 5-41 months; 3 patients (20%) with partial remission are alive with disease after a follow-up period of 8-12.5 months; 6 patients (40%) with no remission expired with a survival time of 3-6 months. Severe anemia and leukopenia (grade 3-4) were seen in 26.66 per cent. Thrombocytopenia grade 4 was seen in 13.33 per cent of cases. Nausea and vomiting occurred in almost all patients. There were no problems with hepatotoxicity, nephrotoxicity, or ototoxicity.
Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Carcinoma de Células Escamosas/tratamiento farmacológico , Cisplatino/administración & dosificación , Femenino , Humanos , Persona de Mediana Edad , Mitomicina , Mitomicinas/administración & dosificación , Recurrencia Local de Neoplasia , Neoplasias del Cuello Uterino/tratamiento farmacológicoRESUMEN
Cervical biopsies were taken from 55 new cases of invasive cervical cancer attending the tumour clinic for detection of human papillomavirus DNA by dot blot hybridization technique. There were 50 patients with squamous cell carcinoma, 4 with adenocarcioma and one with adenosquamous cell carcinoma. The human papillomavirus DNA were detected in 36 cases (65.4%), of which HPV type 16 were detected in 26 cases (47.3%) while type 18 in 10 cases (18.1%). The findings were similar to those of other reports.